M. Worm
Charité
35 Papers
132 Citations
M. Worm is an academic researcher from Charité. The author has contributed to research in topics: Randomized controlled trial & Adverse effect. The author has an hindex of 8, co-authored 35 publications. Previous affiliations of M. Worm include University of Graz.
Chat about Author
Papers
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
A. Wollenberg,Andrew Blauvelt,E. Guttman-Yassky,M. Worm,C Lynde,Jean-Philippe Lacour,Lynda Spelman,Norito Katoh,Hidehisa Saeki,Yves Poulin,A. Lesiak,Leon H Kircik,Leon H Kircik,S.H. Cho,Pedro Herranz,Michael J. Cork,Ketty Peris,Louise Abildgaard Steffensen,Bo Bang,Alexandra Kuznetsova,T.N. Jensen,M.L. Østerdal,Eric L. Simpson +22 more
TL;DR: Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD).
419
Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double‐blind, vehicle‐controlled phase IIa study
TL;DR: Management of chronic hand eczema (CHE) remains a challenge; effective topical treatment is limited to corticosteroids.
86
Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen
J. Kleine-Tebbe,K.-Ch. Bergmann,Frank Friedrichs,T. Fuchs,Kirsten Jung,Ludger Klimek,J. Kühr,W. Lässig,Ute Lepp,Bodo Niggemann,J. Rakoski,Wolfgang Rebien,Harald Renz,Joachim Saloga,Jan C. Simon,H. Sitter,Ch. Virchow,M. Worm +17 more
TL;DR: The guideline on allergen-specific immunotherapy (SIT) was established by the German allergy societies in conjunction with other scientific and medical societies (dermatology, ear-nose-throat, pediatrics, lung and airway diseases) and a patient support group according to criteria of the Association of the Scientific Medical Societies in Germany (AWMF).
59
In-vitro-Diagnostik und molekulare Grundlagen von IgE-vermittelten Nahrungsmittelallergien Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI), des Ärzteverbandes Deutscher Allergologen (ÄDA), der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA), der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI) und der Schweizerischen Gesellschaft für Allergologie und Immunologie (SGAI)
J. Kleine-Tebbe,Barbara Ballmer-Weber,Kirsten Beyer,S. Erdmann,T. Fuchs,M. Henzgen,Isidor Huttegger,Uta Jappe,Lothar Jäger,Ute Lepp,Bodo Niggemann,Martin Raithel,I. Reese,Joachim Saloga,Z. Szäpfalusi,S. Vieths,M. Worm,T. Zuberbier,T. Werfel +18 more
TL;DR: The detection of allergen-specific IgE represents the most important tool for in vitro diagnostic testing of food allergy as mentioned in this paper, which is the most commonly used tool for food allergy diagnosis.
Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts.
J. Ring,M. Worm,A. Wollenberg,Jacob P. Thyssen,Thilo Jakob,L Klimek,Christine Bangert,Sébastien Barbarot,T. Bieber,M S de Bruin-Weller,Pavel V Chernyshov,Stéphanie Christen-Zaech,Michael J. Cork,Ulf Darsow,Carsten Flohr,R. Fölster-Holst,Carlo Gelmetti,U. Gieler,J. Gutermuth,Annice Heratizadeh,DirkJan Hijnen,L.B. von Kobyletzki,B. Kunz,Carle Paul,L. De Raeve,Julien Seneschal,Dagmar Simon,Ph.I. Spuls,J. F. Stalder,Åke Svensson,Z. Szalai,Alain Taieb,Antonio Torrelo,Magdalena Trzeciak,Christian Vestergaard,Thomas Werfel,S. Weidinger,Mette Deleuran +37 more
TL;DR: In this article, a rate of 4,5 severe allergic reactions occurred among 1 million patients vaccinated with the mRNA-based COVID•19 vaccines, which is higher than the generally expected rate of severe allergic reaction to vaccinations of around 1 in 1 million.
25